SCHEMBL1647227

SCHEMBL1647227

Nc1c(Cl)cnnc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30206002 1.00
SCHEMBL30239892 0.81
SCHEMBL6839580 0.81
SCHEMBL5139987 0.81
SCHEMBL30239899 0.81
SCHEMBL15006461 0.77
SCHEMBL21603318 0.77
SCHEMBL384814 0.74
SCHEMBL30124861 0.74
SCHEMBL28309076 0.74 GOT1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090330-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 WO disclosed
WO-2025137437-A1 SOLID FORMS OF A GABAA RECEPTOR MODULATOR AND METHODS OF ITS USE PFIZER INC. (US) 2025-06-26 WO disclosed
US-20250163078-A1 IMIDAZOPYRIDAZINE DERIVATIVE, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2025-05-22 US disclosed
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 EP disclosed
US-20250129044-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2025-04-24 US disclosed
EP-4524139-A1 IMIDAZOPYRIDAZINE SUBSTITUTED BENZENE RING DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE Shanghai Simr Biotechnology Co., Ltd. (CN) 2025-03-19 EP disclosed
EP-4484433-A1 IMIDAZOPYRIDAZINE DERIVATIVE, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2025-01-01 EP disclosed
US-12162841-B2 Process for preparing 4-amino-pyridazines BASF SE (DE) 2024-12-10 US disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 US disclosed
WO-2024220891-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2024-10-24 WO disclosed
EP-2483254-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2012-08-08 EP disclosed
US-20120184553-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-07-19 US disclosed
US-7943615-B2 Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME CORP. (US) 2011-05-17 US disclosed
US-20110105543-A1 NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2011-05-05 US disclosed
WO-2011038572-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-04-07 WO disclosed
EP-2151439-A1 NITROGENATED AROMATIC 6-MEMBERED RING DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE SAME Asubio Pharma Co., Ltd. (JP) 2010-02-10 EP disclosed
US-20090233936-A1 Fused Aminopiperidines as Dipeptidyl Peptidase-4 Inhibitors for the Treatment or Prevention of Diabetes MERCK & CO., INC. (US) 2009-09-17 US disclosed
EP-1962601-A2 FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES Merck & Co., Inc. (US) 2008-09-03 EP disclosed
WO-2007070434-A2 FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2007-06-21 WO disclosed
US-4728355-A RETARDING SENESCENCE IN SOYBEANS AND COTTON FMC CORPORATION (US) 1988-03-01 US disclosed